<p>Mumbai, India, January 28, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).</p><p>Cipla&amp;rsquo;s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer&amp;rsquo;s Depo-Provera&amp;reg;. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera&amp;reg; and its generic equivalents had US sales of approximately $159M for the 12-month period ending November 2018.</p><p>About CIPLA:</p><p>Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.</p><p>Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.</p><p>Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sept&amp;rsquo;18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Aug&amp;rsquo;18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla&amp;rsquo;s work.</p><p>Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement.</p><p>A responsible corporate citizen, Cipla&amp;rsquo;s humanitarian approach to healthcare in pursuit of its purpose of &amp;lsquo;Caring for Life&amp;rsquo; and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.</p><p>For queries, please contact:</p><p>Corporate Communications Investor Relations</p><p>Heena Kanal Naveen Bansal</p><p>E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com</p>